The breakthrough discovery of upregulation of the JAK-STAT signaling pathway as the driving force behind myeloproliferative neoplasms (MPNs) has led to a broadened range of treatment options across the spectrum of MPNs. Myelofibrosis is one of the most common types of MPN and many clinical trials are exploring novel drugs and combinations for its treatment. The JAK inhibitor ruxolitinib became the first JAK inhibitor to receive FDA approval for the treatment of myelofibrosis in 2011, and more recently the FDA granted approval to fedratinib for patients with intermediate-2 or high-risk myelofibrosis.
In this podcast, Srdan Verstovsek, MD, from the MD Anderson Cancer Center, Houston, TX, Ruben Mesa, MD, from the UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, of the MD Anderson Cancer Center, discuss the key updates from clinical trials investigating novel therapies and treatment regimens for patients with myelofibrosis, which were presented at the European Hematology Association (EHA) 2021 meeting.
The post EHA 2021: key trial updates in myelofibrosis appeared first on VJHemOnc.
